Swantje Völler
Universitair docent
- Naam
- Dr. S. Völler
- Telefoon
- 071 5272727
- s.voller@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0003-0587-2775
Meer informatie over Swantje Völler
Promovendi
Meer informatie over Swantje Völler op haar Engelstalige profielpagina.
Universitair docent
- Faculteit der Wiskunde en Natuurwetenschappen
- LACDR
- Divisie Systems Pharmacology and Pharmacy
- Tan Z., Völler S., Sancho‐Araiz A., Knibbe C.A.J. & Moes D.J.A.R. (2025), A systematic evaluation of the dosing regimens for approved targeted therapies and immune checkpoint inhibitors in metastatic renal cell carcinoma from a project OPTIMUS perspective, The Journal of Clinical Pharmacology 65(10): 1187-1207.
- Tan Z., Völler S., Yin A., Rieborn A., Gelderblom H., Hulle T. van der, Knibbe C.A.J. & Moes D.J.A.R. (2025), Model-informed dose optimization of pazopanib in real-world patients with cancer, Clinical Pharmacokinetics 64(5): 715-728.
- Wu Y., Völler S., Goulooze S.C., Allegaert K., Sherwin C.M.T., Rongen A. van, Roofthooft D.W.E., Simons S.H.P., Tibboel D., Flint R.B., Anker J.N. van den & Knibbe C.A.J. (2025), A novel maturation equation for hepatic clearance across preterm, term neonates, children, and adults: application to paracetamol and its metabolite, The Journal of Clinical Pharmacology 65(12): 1829-1843.
- Tan Z., Völler S., Yin A., Rieborn A., Gelderblom A.J., Hulle T. van der, Knibbe C.A.J. & Moes D.J.A.R. (2024), Population pharmacokinetics of cabozantinib in metastatic renal cell carcinoma patients: towards drug expenses saving regimens, Clinical Pharmacokinetics 63(6): 857-869.
- Wu Y., Allegaert K., Flint R.B., Goulooze S.C., Valitalo P.A.J., Hoog M. de, Mulla H., Sherwin C.M.T., Simons S.H. P., Krekels E.H.J., Knibbe C.A.J. & Völler S. (2024), When will the glomerular filtration rate in former preterm neonates catch up with their term peers?, Pharmaceutical Research 41(4): 637-649.
- Wu Y., Völler S., Krekels E.H.J., Roofthooft D.W.E., Simons S.H.P., Tibboel D., Flint R.B. & Knibbe C.A.J. (2023), Maturation of paracetamol elimination routes in preterm neonates born below 32 weeks of gestation, Pharmaceutical Research 40(9): 2155-2166.
- Wu Y., Völler S., Flint R.B., Simons S.H.P., Allegaert K., Fellman V. & Knibbe C.A.J. (2022), Pre- and postnatal maturation are important for fentanyl exposure in preterm and term newborns: a pooled population pharmacokinetic study, Clinical Pharmacokinetics 61: 401-412.
- Engbers A.G.J., Flint R.B., Völler S., Reiss I., Liem K.D., Alffenaar J.W.C., Tibboel D., Simons S., Knibbe C.A.J. & Bruggemann R.J. (2022), Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants, Archives of disease in childhood 107(4): 400-406.
- Wu Y.J., Allegaert K., Flint R.B., Simons S.H.P., Krekels E.H.J., Knibbe C.A.J. & Völler S. (2022), Prediction of glomerular filtration rate maturation across preterm and term neonates and young infants using inulin as marker, AAPS Journal 24(2): 38.
- Engbers A.G.J., Völler S., Flint R.B., Goulooze S.C., Klerk J. de, Krekels E.H.J., Dijk M. van, Willemsen S.P., Reiss I.K.M., Knibbe C.A.J. & Simons S.H.P. (2022), The effect of ibuprofen exposure and patient characteristics on the closure of the patent Ductus Arteriosus in preterm infants, Clinical Pharmacology & Therapeutics 112(2): 307-315.
- Flint R.B., Simons S.H.P., Andriessen P., Liem K.D., Degraeuwe P.L.J., Reiss I.K.M., Ter Heine R., Engbers A.G.J., Koch B.C.P., Groot R. de, Burger D.M., Knibbe C.A..J. & Völler S. (2021), The bioavailability and maturing clearance of doxapram in preterm infants, Pediatric Research 89: 1268-1277.
- Engbers A.G.J., Voller S., Poets C.F., Knibbe C.A.J., Reiss I.K.M., Koch B.C.P., Flint R.B. & Simons S.H.P. (2021), The pharmacokinetics of caffeine in preterm newborns: no influence of doxapram but important maturation with age, Neonatology 118(1): 106-113.
- Voller S., Flint R.B., Simons S.H.P. & Knibbe C.A.J. (2021), Comment on: "Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II", Clinical Pharmacokinetics 60: 677-679.
- Aulin L.B.S., Lange D.W. de, Saleh M.A.A., Graaf P.H. van der, Völler S. & Hasselt J.G.C. (2021), Biomarker-guided individualization of antibiotic therapy, Clinical Pharmacology & Therapeutics 110(2): 346-360.
- Kurul S., Fiebig K., Flint R.B., Reiss I.K.M., Kuster H., Simons S.H.P., Völler S. & Taal H.R. (2021), Knowledge gaps in late-onset neonatal sepsis in preterm neonates: a roadmap for future research, Pediatric Research 91: 368-379.
- Engbers A.G.J., Flint R.B., Voller S., Klerk J.C.A., Reiss I.K.M., Andriessen P., Liem K.D., Degraeuwe P.L.J., Croubels S., Millecam J., Allegaert K., Simons S.H.P. & Knibbe C.A.J. (2020), Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus, British Journal of Clinical Pharmacology 86(10): 2028-2039.
- Völler S., Flint R.B., Andriessen P., Allegaert K., Zimmermann L.J.I., Liem K.D., Koch B.C.P., Simons S.H.P. & Knibbe C.A.J. (2019), Rapidly maturing fentanyl clearance in preterm neonates, Archives of Disease in Childhood. Fetal and Neonatal Edition 104(6): F598-F603.
- Voller S., Flint R.B., Beggah F., Reiss I., Andriessen P., Zimmermann L.J.I., Anker J.N. van den, Liem K.D., Koch B.C.P., Wildt S. de, Knibbe C.A.J. & Simons S.H.P. (2019), Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model, The Journal of Clinical Pharmacology 59(10): 1300-1308.
- Goulooze S.C., Völler S., Valitalo P.A.J., Calvier E.A.M., Aarons L., Krekels E.H.J. & Knibbe C.A.J. (2019), The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models, Clinical Pharmacokinetics 58(1): 131-138.
- Völler S., Pichlmeier U., Zens A. & Hempel G. (2018), Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemi, Cancer Chemotherapy and Pharmacology 81(2): 305-314.
- Völler S., Flint R.B., Stolk L.M., Degraeuwe P.L.J., Simons S.H.P., Pokorna P., Burger D.M., Groot R. de, Tibboel D. & Knibbe C.A.J. (2017), Model-based clinical dose optimization for phenobarbital in neonates: an illustration of the importance of data sharing and external validation, European Journal of Pharmaceutical Sciences 109: S90-S97.
- Flint R., Weteringen W.V., Völler S., Poppe J.A., Koch B.C., Groot R., Tibboel D., Knibbe C.A., Reiss I.K. & Simons S.H. (2017), Big data analyses for continuous evaluation of pharmacotherapy: A proof of principle with doxapram in preterm infants, Current Pharmaceutical Design 23(38): 5919-5927.
- Völler S., Hempel G., Würthwein G., Boddy A.V., Krischke M., André N., D'Incalci M., Bisogno G. & Boos J. (2017), Towards a Model-Based Dose Recommendation for Doxorubicin in Children, Clinical Pharmacokinetics 56(3): 215-223.
- Krischke M., Hempel G., Völler S., André N., D'Incalci M., Bisogno G., Köpcke W., Borowski M., Herold R., Boddy A.V. & Boos J. (2016), Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial, Cancer Chemotherapy and Pharmacology 78(6): 1175-1184.
- Lanckohr C., Horn D., Völler S., Hempel G., Fobker M., Welp H., Koeck R. & Ellger B. (2016), Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery, Journal of Thoracic and Cardiovascular Surgery 152(2): 603-610.
- Völler S., Boos J., Krischke M., Würthwein G., Kontny N.E., Boddy A.V. & Hempel G. (2015), Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer, Clinical Pharmacokinetics 54(11): 1139-1149.